The past week highlighted both the lofty and the dire in Mexico healthcare industry. On the one hand, the country focused its attention beyond the stratosphere with the fourth congress related to healthcare in space, while on the other, the National Human Rights Commission denounced the country’s low healthcare expenditure – and a local association indicated that the low investment itself is not managed properly.
Internationally, Wednesday marked World Day Against Pain to increase awareness of the impact of chronic pain, which affects 1.5 billion people across the globe, while Merck and Roche bet on cancer treatments and Canada legalized cannabis.
In our Interview of the Week, Mexico Health Review spoke with Javier Okhuysen, Director General of salauno, regarding the main vision problems affecting Mexicans and what can be done to address them.
Ready? Jump into the top headlines of the past week:
UNAM held the fourth Mexican Congress of Medicine and Healthcare in Space. The event offered seminars and workshops for students and healthcare professionals.
Luis Raúl González Pérez, President of the National Human Rights Commission stated that Mexico is among the lowest investors in healthcare, doling out about US$1,080 a year per person.
The Ministry of Health encouraged people to get a flu shot. Since Sept. 30, Mexico has diagnosed 25 flu cases, of which 21 corresponded to the virus AH1N1.
Mexicans Against Corruption and Impunity (MCCI) denounced the inefficient use of hospitals built under a public-private association (PPA), costing the government MX$656 million. In response, representatives from the incoming administration indicated that they would closely follow the development of PPAs.
Canada legalized marijuana for recreational use and supplies quickly started running low, but the stocks of cannabis companies are soaring.
Merck’s Keytruda met major endpoints in a kidney cancer trial together with Pfizer’s Inlyta. Keytruda has already been approved for the treatment of other types of cancer, including lung.
Pharma giant Roche and SQZ Biotech expand a 2015 collaboration for the development of cancer therapies to over US$1.375 billion.